ID: ALA3978380

Max Phase: Preclinical

Molecular Formula: C26H22N6O5S

Molecular Weight: 530.57

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCc1cccc(-c2ccc(CS(=O)(=O)Cc3n[nH]c(=O)[nH]3)cc2)c1)c1nc2ccccc2c(=O)[nH]1

Standard InChI:  InChI=1S/C26H22N6O5S/c33-24-20-6-1-2-7-21(20)28-23(30-24)25(34)27-13-17-4-3-5-19(12-17)18-10-8-16(9-11-18)14-38(36,37)15-22-29-26(35)32-31-22/h1-12H,13-15H2,(H,27,34)(H,28,30,33)(H2,29,31,32,35)

Standard InChI Key:  GTZKIGXVCZWIAR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 530.57

Molecular Weight (Monoisotopic): 530.1372

AlogP: 2.05

#Rotatable Bonds: 8

Polar Surface Area: 170.53

Molecular Species: ACID

HBA: 7

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 6.39

CX Basic pKa: 1.49

CX LogP: 1.72

CX LogD: 0.80

Aromatic Rings: 5

Heavy Atoms: 38

QED Weighted: 0.24

Np Likeness Score: -1.29

References

1. Nara H, Sato K, Kaieda A, Oki H, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M..  (2016)  Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.,  24  (23): [PMID:27825552] [10.1016/j.bmc.2016.09.009]

Source

Source(1):

• Scientific Literature